Zacks Investment Research Comments on MediciNova, Inc.’s Q1 2018 Earnings (MNOV)

Zacks Investment Research Comments on MediciNova, Inc.’s Q1 2018 Earnings (MNOV)

MediciNova, Inc. (NASDAQ:MNOV) – Research analysts at Zacks Investment Research issued their Q1 2018 earnings estimates for shares of MediciNova in a research report issued on Friday. Zacks Investment Research analyst D. Bautz anticipates that the biopharmaceutical company will post earnings of ($0.12) per share for the quarter. Zacks Investment Research also issued estimates for MediciNova’s Q2 2018 earnings at ($0.11) EPS, Q3 2018 earnings at ($0.11) EPS, Q4 2018 earnings at ($0.11) EPS and FY2020 earnings at ($0.41) EPS.

A number of other equities research analysts have also commented on MNOV. ValuEngine raised shares of MediciNova from a “sell” rating to a “hold” rating in a research note on Wednesday, February 7th. BidaskClub raised shares of MediciNova from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, February 7th.

Shares of MediciNova (NASDAQ:MNOV) opened at $10.90 on Monday. MediciNova has a 12 month low of $4.40 and a 12 month high of $11.45. The company has a market cap of $446.13, a price-to-earnings ratio of -34.06 and a beta of 0.38.

Several large investors have recently bought and sold shares of MNOV. Deutsche Bank AG boosted its stake in shares of MediciNova by 151.6% in the 4th quarter. Deutsche Bank AG now owns 78,345 shares of the biopharmaceutical company’s stock valued at $506,000 after purchasing an additional 47,209 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of MediciNova by 123.3% in the 4th quarter. Renaissance Technologies LLC now owns 79,500 shares of the biopharmaceutical company’s stock valued at $514,000 after purchasing an additional 43,900 shares during the last quarter. Alps Advisors Inc. bought a new stake in shares of MediciNova in the 4th quarter valued at $259,000. Northern Trust Corp boosted its stake in shares of MediciNova by 10.6% in the 2nd quarter. Northern Trust Corp now owns 368,599 shares of the biopharmaceutical company’s stock valued at $1,939,000 after purchasing an additional 35,331 shares during the last quarter. Finally, Paloma Partners Management Co bought a new stake in shares of MediciNova in the 4th quarter valued at $198,000. 22.00% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/19/zacks-investment-research-comments-on-medicinova-inc-s-q1-2018-earnings-mnov.html.

MediciNova Company Profile

Medicinova, Inc is a biopharmaceutical company. The Company focuses on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical needs and a commercial focus on the United States market. Its pipeline includes MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine) and MN-029 (denibulin).

Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.

MediciNova, Inc. (NASDAQ:MNOV) – Stock analysts at Zacks Investment Research issued their Q1 2018 earnings per share estimates for MediciNova in a research note issued to investors on Friday. Zacks Investment Research analyst D. Bautz expects that the biopharmaceutical company will post earnings per share of ($0.12) for the quarter. Zacks Investment Research also issued estimates for MediciNova’s Q2 2018 earnings at ($0.11) EPS, Q3 2018 earnings at ($0.11) EPS, Q4 2018 earnings at ($0.11) EPS and FY2020 earnings at ($0.41) EPS.

Other analysts also recently issued reports about the stock. BidaskClub raised shares of MediciNova from a “hold” rating to a “buy” rating in a research note on Tuesday, January 30th. ValuEngine raised shares of MediciNova from a “sell” rating to a “hold” rating in a research note on Wednesday, February 7th.

MediciNova (NASDAQ:MNOV) opened at $10.90 on Monday. The stock has a market capitalization of $446.13, a price-to-earnings ratio of -34.06 and a beta of 0.38. MediciNova has a twelve month low of $4.40 and a twelve month high of $11.45.

A number of large investors have recently made changes to their positions in MNOV. Teachers Advisors LLC raised its stake in MediciNova by 7.2% during the 2nd quarter. Teachers Advisors LLC now owns 54,649 shares of the biopharmaceutical company’s stock valued at $287,000 after purchasing an additional 3,673 shares during the period. TIAA CREF Investment Management LLC raised its stake in MediciNova by 7.2% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 90,295 shares of the biopharmaceutical company’s stock valued at $475,000 after purchasing an additional 6,035 shares during the period. Northern Trust Corp raised its stake in MediciNova by 10.6% during the 2nd quarter. Northern Trust Corp now owns 368,599 shares of the biopharmaceutical company’s stock valued at $1,939,000 after purchasing an additional 35,331 shares during the period. Vanguard Group Inc. raised its stake in MediciNova by 1.0% during the 2nd quarter. Vanguard Group Inc. now owns 1,197,716 shares of the biopharmaceutical company’s stock valued at $6,300,000 after purchasing an additional 12,249 shares during the period. Finally, Voya Investment Management LLC raised its stake in MediciNova by 22.9% during the 2nd quarter. Voya Investment Management LLC now owns 19,341 shares of the biopharmaceutical company’s stock valued at $102,000 after purchasing an additional 3,603 shares during the period. 22.00% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This story was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/19/zacks-investment-research-comments-on-medicinova-inc-s-q1-2018-earnings-mnov.html.

About MediciNova

Medicinova, Inc is a biopharmaceutical company. The Company focuses on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical needs and a commercial focus on the United States market. Its pipeline includes MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine) and MN-029 (denibulin).

Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply